High Technology Diagnostic Center Ltd., which is part of Rusatom Healthcare A.Ş, the medical unit of Russian State Atomic Energy Agency Rosatom, operates in the field of medicine. Şti received a registration certificate for the radiopharmaceutical drug “Fluorodeoxyglucose, 18-F” from the Russian Ministry of Health.
According to the data of the World Health Organization, the number of detected cancer cases is increasing every year. In 2020, 19,3 million cases were detected in the world and 591 thousand cases in Russia. Diagnosis using radiopharmaceuticals enables tens of millions of diseases worldwide to be detected at an earlier stage and to initiate treatment in a timely manner.
Fluorodeoxyglucose solution is designed for intravenous administration as a diagnostic tool in Positron Emission Tomography (PET) for early detection of malignant neoplasms, differential diagnosis of malignant tumors, monitoring the effectiveness of treatment for these tumors. The drug has a short half-life of 109 minutes and is completely eliminated from the body within a few hours.
Yüksek Teknoloji Diagnostic Center Ltd.Şti. is a company licensed by the Russian Ministry of Industry and Trade for the production of radiopharmaceutical drugs. Equipped with a Russian-made SS-18/9M cyclotron, the production facility has been operating since 2014.
Obtaining the registration certificate for the drug “Fluorodeoxyglucose, 18-F” by the Hi-Tech Diagnostic Center Ltd.Şti will fully meet the pharmaceutical needs of health centers in Moscow and the Moscow Region.
Rusatom Healthcare currently supplies a wide range of radiopharmaceuticals and medical products manufactured by Rosatom sub-units for 180 Russian health centers.
Natalya Komarova, General Manager of Rusatom Healthcare A.Ş., said: “For Rusatom Healthcare, which contributes to the state in comprehensive development of medical technologies, raising the average age of the population and improving the quality of life, our citizens have access to modern radionuclide diagnostic and treatment methods. is extremely important. Obtaining the certificate of registration for fluorodeoxyglucose 18-F will enable thousands of Russians to be diagnosed and successfully treated on time.”
The Rusatom Healthcare division plans to expand the range of manufactured radiopharmaceuticals. Rusatom Healthcare A.Ş., from the Russian Federal Autonomous Institution Glavgoexpertiza last year, chemist L. Ya. He received a positive report for the modern pharmaceutical production design of isotope products for medical purposes, the accounting documents and the results of the engineering research of the plant at NIFKhI A.Ş., bearing the name of Karpova. In 2025, a facility for the production of radiopharmaceuticals in accordance with international GMP (good manufacturing practices) standards will be established in Russia. With the establishment of the plant, Rosatom plans to change its position in the Russian radiopharmaceutical market, meaning that the production in the city of Obninsk will become one of the leading productions in the field of radiopharmaceuticals.
In addition, the Rusatom Healthcare unit also manufactures medical equipment for radiation and brachytherapy. Rusatom Healthcare carries out projects for the construction of nuclear medicine centers in various regions of Russia and establishes a multifunctional center chain for the operation and sterilization of medical devices.
Be the first to comment